LEGATO Project

Phase III randomised pragmatic clinical trial on Recurrent Glioblastoma conducted as part of the EU's Cancer Mission

[LEGATO Project @Legato_Horizon]

https://t.co/T4hjrcwide

[LEGATO Project @Legato_Horizon]

@EORTC @EU_Commission
#GlioblastomaAwarenessDay #Glioblastoma #BrainTumour #CancerResearch #ClinicalResearch #legato_horizon

[LEGATO Project @Legato_Horizon]

Today is Glioblastoma Awareness Day.

[LEGATO Project @Legato_Horizon]

On Glioblastoma Awareness Day, we recognise everyone affected by glioblastoma, their families and caregivers, and all those working towards better treatment options.

[LEGATO Project @Legato_Horizon]

📢 The latest LEGATO Newsletter is now available!

In this issue, we share several important updates from the LEGATO project:

[LEGATO Project @Legato_Horizon]

#legato_horizon #glioblastoma #recurrentglioblastoma #NeuroOncology #clinicaltrials #cancerresearch #EvidenceBasedCare #HorizonEurope

@EU_Commission @EORTC

[LEGATO Project @Legato_Horizon]

Read the full newsletter here:
https://t.co/2zHqmX53zk
Find your nearest clinical site here:
https://t.co/O7jUtMFECV
Visit the LEGATO website here:
https://t.co/oSXyzLEFJj

[LEGATO Project @Legato_Horizon]

#legato_horizon #glioblastoma #BrainCancerAwarenessr #cancerresearch #clinicaltrials #NeuroOncology #HorizonEurope #EUCancerMission

[LEGATO Project @Legato_Horizon]

The latest LEGATO Project newsletter will be available soon!

This edition includes updates on study enrolment, collaboration across participating clinical sites, and recent research highlighting evidence gaps in glioblastoma care.

[LEGATO Project @Legato_Horizon]

For full updates and future news, subscribe to the LEGATO newsletter: https://t.co/KiVBX8IPs7
@EORTC - European Organisation for Research and Treatment of Cancer
@EU_Commission

[LEGATO Project @Legato_Horizon]

#legato_horizon #glioblastoma #ClinicalResearch #collaboration #NeuroOncology

[LEGATO Project @Legato_Horizon]

We are pleased to share an important milestone: 50% of the planned patients have now been enrolled in the study, bringing the trial halfway toward the accrual goal of 411 patients.

[LEGATO Project @Legato_Horizon]

This milestone was made possible by dedicated patients and professionals, real effort, and a shared commitment to defining a new evidence-based standard of care for recurrent glioblastoma, a very challenging disease.
@EORTC @EU_Commission